Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade - MarketBeat
14 hours ago • Google News
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
14 hours ago • Google News
21 hours ago • Google News